CU23244A1 - Formulacion vacunal potenciada por la combinacion de un adn con un antigeno - Google Patents

Formulacion vacunal potenciada por la combinacion de un adn con un antigeno

Info

Publication number
CU23244A1
CU23244A1 CU20010171A CU20010171A CU23244A1 CU 23244 A1 CU23244 A1 CU 23244A1 CU 20010171 A CU20010171 A CU 20010171A CU 20010171 A CU20010171 A CU 20010171A CU 23244 A1 CU23244 A1 CU 23244A1
Authority
CU
Cuba
Prior art keywords
antigen
components
potentiated
dna
combination
Prior art date
Application number
CU20010171A
Other languages
English (en)
Inventor
Lasa Alexis Musacchio
Obregon Julio Cesar Alvarez
Donato Gillian Martinez
Ponce De Le Alvarez-Lajonchere
Rivero Nelson Acosta
Grillo Juan Morales
Carrera Santiago Duenas
Feyt Rolando Pajon
Rodriguez Ariel Vina
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Priority to CU20010171A priority Critical patent/CU23244A1/es
Priority to MYPI20022620A priority patent/MY134885A/en
Priority to AU2002325783A priority patent/AU2002325783B2/en
Priority to US10/484,112 priority patent/US20040234543A1/en
Priority to PCT/CU2002/000005 priority patent/WO2003007986A2/es
Priority to ES02760072T priority patent/ES2393546T3/es
Priority to JP2003513591A priority patent/JP4217611B2/ja
Priority to BR0211181-0A priority patent/BR0211181A/pt
Priority to CNB028142829A priority patent/CN1241644C/zh
Priority to RU2004104357A priority patent/RU2294212C2/ru
Priority to CA 2453260 priority patent/CA2453260C/en
Priority to EP20020760072 priority patent/EP1417973B1/en
Priority to MXPA04000431A priority patent/MXPA04000431A/es
Priority to KR1020047000574A priority patent/KR100905249B1/ko
Priority to ARP020102614 priority patent/AR034771A1/es
Priority to ZA200400286A priority patent/ZA200400286B/en
Publication of CU23244A1 publication Critical patent/CU23244A1/es
Priority to US12/430,534 priority patent/US8691234B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Formulacion de antígenos vacunales, la cual contiene como componentes principales: a-) uno o varios ADN que expresan una o varias proteínas en el individuo inmunizado y b-) un antígeno viral, en proporciones adecuadas. La novedad de la invencion estA dada por el efecto potenciador que ejerce al menos uno de los componentes sobre la respuesta inmune generada contra el otro. Desarrollo de nuevas formulaciones, minimizando el nUmero de componentes que sean capaces de ampliar y potenciar el espectro de respuesta inmune contra diferentes entidades patogÉnicas y de generar vacunas combinadas contra entidades patogenas. Estas formulaciones pueden ser aplicadas en la industria farmacÉutica para uso profilActico y/o terapÉutico en humanos.
CU20010171A 2001-07-16 2001-07-16 Formulacion vacunal potenciada por la combinacion de un adn con un antigeno CU23244A1 (es)

Priority Applications (17)

Application Number Priority Date Filing Date Title
CU20010171A CU23244A1 (es) 2001-07-16 2001-07-16 Formulacion vacunal potenciada por la combinacion de un adn con un antigeno
MYPI20022620A MY134885A (en) 2001-07-16 2002-07-10 Vaccine formulation potentiated by the combination of dna and an antigen
BR0211181-0A BR0211181A (pt) 2001-07-16 2002-07-12 Formulação vacinal
RU2004104357A RU2294212C2 (ru) 2001-07-16 2002-07-12 Вакцинный состав, потенцированный комбинацией днк и антигена
PCT/CU2002/000005 WO2003007986A2 (es) 2001-07-16 2002-07-12 Formulacion vacunal potenciada por la combinacion de un adn con un antigeno
ES02760072T ES2393546T3 (es) 2001-07-16 2002-07-12 Formulación de vacuna potenciada mediante la combinación de un ADN con un antígeno
JP2003513591A JP4217611B2 (ja) 2001-07-16 2002-07-12 Ｄｎａおよび抗原の併用により作用増強したワクチン製剤
AU2002325783A AU2002325783B2 (en) 2001-07-16 2002-07-12 Vaccine formulation potentiated by the combination of a DNA and an antigen
CNB028142829A CN1241644C (zh) 2001-07-16 2002-07-12 被dna和抗原组合增效的疫苗制剂
US10/484,112 US20040234543A1 (en) 2001-07-16 2002-07-12 Vaccine formulation potentiated by the combination of a dna and an antigen
CA 2453260 CA2453260C (en) 2001-07-16 2002-07-12 Vaccine formulation potentiated by the combination of a dna and an antigen
EP20020760072 EP1417973B1 (en) 2001-07-16 2002-07-12 Vaccine formulation potentiated by the combination of a dna and an antigen
MXPA04000431A MXPA04000431A (es) 2001-07-16 2002-07-12 Formulacion vacunal potenciada por la combinacion de un adn con un antigeno.
KR1020047000574A KR100905249B1 (ko) 2001-07-16 2002-07-12 Ｄｎａ와 항원의 조합에 의해 효능이 증강된 백신포뮬레이션
ARP020102614 AR034771A1 (es) 2001-07-16 2002-07-12 Formulacion vacunal potenciada por la combinacion de un adn con un antigeno
ZA200400286A ZA200400286B (en) 2001-07-16 2004-01-14 Vaccine formulation potentiated by the combination of a DNA and an antigen.
US12/430,534 US8691234B2 (en) 2001-07-16 2009-04-27 Vaccine formulation potentiated by the combination of DNA and an antigen

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20010171A CU23244A1 (es) 2001-07-16 2001-07-16 Formulacion vacunal potenciada por la combinacion de un adn con un antigeno

Publications (1)

Publication Number Publication Date
CU23244A1 true CU23244A1 (es) 2007-10-17

Family

ID=40091632

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20010171A CU23244A1 (es) 2001-07-16 2001-07-16 Formulacion vacunal potenciada por la combinacion de un adn con un antigeno

Country Status (16)

Country Link
US (2) US20040234543A1 (es)
EP (1) EP1417973B1 (es)
JP (1) JP4217611B2 (es)
KR (1) KR100905249B1 (es)
CN (1) CN1241644C (es)
AR (1) AR034771A1 (es)
AU (1) AU2002325783B2 (es)
BR (1) BR0211181A (es)
CA (1) CA2453260C (es)
CU (1) CU23244A1 (es)
ES (1) ES2393546T3 (es)
MX (1) MXPA04000431A (es)
MY (1) MY134885A (es)
RU (1) RU2294212C2 (es)
WO (1) WO2003007986A2 (es)
ZA (1) ZA200400286B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23496A1 (es) * 2004-09-03 2010-02-23 Ct Ingenieria Genetica Biotech Composición vacunal contra el virus de la hepatitis c
EP1844142B1 (en) * 2005-01-20 2015-08-12 Nature Technology Corporation Vectors and methods for genetic immunization
AU2008262478B9 (en) 2007-05-29 2014-06-19 Aldevron, L.L.C. Vectors and methods for genetic immunization
CN104830789A (zh) * 2015-05-05 2015-08-12 杨光华 基于hcv1抗原的dc细胞、靶向性免疫细胞群及其制备方法和用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4040339C2 (de) * 1989-12-18 1999-07-08 Wellcome Found Virales Agens
CA2044296A1 (en) * 1990-06-12 1991-12-13 Hiroaki Okamoto Oligonucleotide primers, and their application for high-fidelity detection of non-a, non-b hepatitis virus
US7070790B1 (en) * 1993-06-29 2006-07-04 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of the envelope 1 and core genes of isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines
US6689757B1 (en) * 1996-02-12 2004-02-10 M.L. Laboratories Plc Methods for vaccination and vaccines therefor
CU22642A1 (es) * 1996-12-12 2000-12-22 Ct Ingenieria Genetica Biotech Secuencia de adnc derivadas del genoma del virus de la hepatitis c y su uso
CN1044092C (zh) 1997-02-26 1999-07-14 上海医科大学 抗原－抗体－重组dna复合型疫苗
FR2760367B1 (fr) * 1997-03-06 1999-04-30 Pasteur Merieux Serums Vacc Composition vaccinale destinee a la prevention ou au traitement des hepatites c
DE69841015D1 (de) * 1997-05-06 2009-09-10 Novartis Vaccines & Diagnostic Intrazelluläre herstellung von verkürztem hepatitis c-polypeptid e2
US6153421A (en) * 1997-07-18 2000-11-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Cloned genomes of infectious hepatitis C viruses and uses thereof
GB9726555D0 (en) * 1997-12-16 1998-02-11 Smithkline Beecham Plc Vaccine
DE19915178A1 (de) * 1999-04-03 2000-10-05 Univ Mainz Johannes Gutenberg Hepatitis C Virus Zellkultursystem
US7329408B2 (en) * 1999-12-01 2008-02-12 Novartis Vaccines And Diagnostics, Inc. Eliciting HCV-specific antibodies

Also Published As

Publication number Publication date
MY134885A (en) 2007-12-31
ZA200400286B (en) 2004-10-04
RU2294212C2 (ru) 2007-02-27
CN1529616A (zh) 2004-09-15
US20040234543A1 (en) 2004-11-25
EP1417973B1 (en) 2012-08-29
KR20040028924A (ko) 2004-04-03
WO2003007986A8 (es) 2004-04-29
RU2004104357A (ru) 2005-07-10
CA2453260C (en) 2013-03-19
WO2003007986A2 (es) 2003-01-30
US20100316669A1 (en) 2010-12-16
MXPA04000431A (es) 2004-03-18
CN1241644C (zh) 2006-02-15
AU2002325783B2 (en) 2006-08-17
AR034771A1 (es) 2004-03-17
CA2453260A1 (en) 2003-01-30
ES2393546T3 (es) 2012-12-26
EP1417973A2 (en) 2004-05-12
JP2004537552A (ja) 2004-12-16
KR100905249B1 (ko) 2009-06-29
BR0211181A (pt) 2004-08-10
US8691234B2 (en) 2014-04-08
JP4217611B2 (ja) 2009-02-04
WO2003007986A3 (es) 2004-03-04

Similar Documents

Publication Publication Date Title
AR032597A1 (es) Uso de antigenos del virus de la gripe inactivado, en la preparacion de vacunas de una sola dosis intranasal; metodo para la profilaxis de enfermedades o de infecciones gripales en pacientes; equipos que comprenden dichas vacunas en dosis unicas y metodo para fabricar vacunas para la gripe para apli
ES2157447T3 (es) Composicion de vacuna que comprende un antigeno de polisacarido conjugado adsorbido en fosfato de aluminio.
CR11122A (es) Vacuna de influenza de emulsion de aceite en agua
NO20023829L (no) Proteosom influensavaksine
EP1594536A4 (en) ADJUVANT INFLUENZA VACCINE
IS4518A (is) Nýtt lyfjaform fyrir bóluefni
TW200722101A (en) Novel composition
MX9702336A (es) Composiciones de vacuna.
DK1361890T3 (da) Influenzavaccineformuleringer til intradermal indgift
PT1187629E (pt) Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
CY1113078T1 (el) Συνθεση πολυσθενους εμβολιου
FR2814958B1 (fr) Composition vaccinale
AR014182A1 (es) Composiciones de vacunas utiles para el tratamiento o profilaxis de tumores o lesiones inducidas por hpv; procedimiento para prevenir o tratar tumoresinducidos por hpv y procedimiento para preparar dichas composiciones
AR023535A1 (es) Nuevas composiciones.
BR112023019301A2 (pt) Formulações de vacina de coronavírus
GB2386072A (en) Novel vaccine
DK1259259T3 (da) Mucosal adjuvansformulering
ATE458496T1 (de) Hiv-vakzine und anwendungsverfahren
ZA202400113B (en) Adjuvanted inactivated recombinant rabies virus vectored coronavirus vaccine formulations
AR034771A1 (es) Formulacion vacunal potenciada por la combinacion de un adn con un antigeno
AR038311A1 (es) Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes
CU23496A1 (es) Composición vacunal contra el virus de la hepatitis c
WO2002036160A3 (es) Método de obtención de estructuras antigénicas que potencian la reactividad cruzada específica
UY28706A1 (es) Proteoliposomas y sus derivados como adyuvantes inductores de respuesta citotóxica y las formulaciones resultantes
AR027738A1 (es) Composicion coadyuvante, composiciones de vacunas que incluyen dicha composicion coadyuvante; procedimiento de induccion de inmunorespuestas antigenicas enmamiferos y procedimiento de tratamiento donde se aplican dichas vacunas